Clearwater has advised Banook Group, a global provider of cardiac, imaging and endpoint adjudication central services to the pharmaceutical, biotechnology and medical sectors, alongside Turenne Capital, a private equity company, on the acquisition of Nabios GmbH, a German company that specialises in cardiac safety assessments in clinical trials of drugs intended for human health.
Founded in 1998 and based in Munich, Germany, Nabios GmbH has developed its expertise in cardiac safety research for clinical drug trials for human health. The company assists pharmaceutical laboratories, CROs and clinical pharmacology units, mainly in the conducting of the first phase of clinical trials for cardiac safety assessment. Nabios GmbH has built a solid relationship with its clients, mainly based in Germany, and has seen an increase in revenue, even during the pandemic.
Founded in 1999, the Banook Group has related and complementary expertise in cardiac safety studies for clinical drug trials as it focuses on Phase I studies but also extends to Phase II and III. Over the past few years, Banook has developed a range of services in image analysis and adjudication for its clients based in Europe, as well as in America and Asia.
The strengthening of the Group in cardiac safety assessment comes in the context of a major consolidation movement in recent months with the merger of major players in the US. The acquisition of Nabios GmbH will enable the Banook Group to become a European leader of significant size, making it more competitive on larger bids from laboratories or subcontractors of clinical studies which generate significant revenues.
